| Patent application number | Description | Published |
|---|
| 20090146549 | LIGHT EMITTING DEVICE AND ILLUMINATION DEVICE - An LED with a semiconductor light emitting element that emits a blue or a blue-violet light, and a fluorescent material that absorbs some or all of the light emitted from the element and emits a fluorescent light of a wavelength different from the absorbed light. The fluorescent material is a mixed fluorescent material obtained by mixing a first fluorescent material that emits a blue-green or a green light, a second fluorescent material that has a peak emission wavelength longer than that of the first fluorescent material and emits a green or a yellow-green light, a third fluorescent material that has a 1 peak emission wavelength longer than that of the second fluorescent material and emits a yellow-green, a yellow or a yellow-red light, and a fourth fluorescent material that has a peak emission wavelength longer than that of the third fluorescent material and emits a yellow-red or a red light. | 06-11-2009 |
| 20090161366 | PORCELAIN ENAMEL SUBSTRATE FOR MOUNTING LIGHT EMITTING DEVICE AND METHOD OF MANUFACTURING THE SAME, LIGHT EMITTING DEVICE MODULE, ILLUMINATION DEVICE, DISPLAY UNIT AND TRAFFIC SIGNAL - A porcelain enamel substrate ( | 06-25-2009 |
| 20110058819 | OPTICAL TRANSMISSION DEVICE - Provided is an optical transmission device which includes: an optical transmission unit including a light-emitting element; an optical reception unit including a static current source generating bias current for driving the light-emitting element; a light-transmitting medium optically connecting the light-emitting element and a light-receiving element to each other; and an electricity-transmitting medium transmitting the bias current from the static current source to the light-emitting element. | 03-10-2011 |
| 20120275747 | OPTICAL COUPLING STRUCTURE AND OPTICAL TRANSRECEIVER MODULE - Provided is an optical coupling structure including an optical semiconductor element including a light receiving/emitting portion, an optical transmission path having an optical axis that intersects the optical axis of the optical semiconductor element at a predetermined angle, and an optical coupling portion configured to convert the optical path between the optical semiconductor element and the optical transmission path and optically couple them. The optical coupling portion is made of a resin that is transparent with respect to a transmitted light, the resin adhering to both at least a portion of the light receiving/emitting portion and at least a portion of the end portion of the optical transmission path, and the optical semiconductor element and the optical transmission path are bonded to each other with the resin itself that constitutes the optical coupling portion. | 11-01-2012 |
| Patent application number | Description | Published |
|---|
| 20100041074 | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-GRP78 ANTIBODY AS ACTIVE INGREDIENT - An object of the present invention is to provide novel pharmaceutical compositions using anti-GRP78 antibodies. More particularly, the present invention aims to provide a novel method of cancer treatment using anti-GRP78 antibodies, novel cell growth inhibitors and anticancer agents that contain anti-GRP78 antibodies, as well as novel anti-GRP78 antibodies. | 02-18-2010 |
| 20100061933 | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT - An anti-HB-EGF antibody having an internalizing activity is disclosed. A cytotoxic substance is preferably bound to the anti-HB-EGF antibody of the present invention. Also provided are an anti-cancer agent and a cell proliferation inhibitor, which comprise the antibody of the present invention as an active ingredient, a method of treating cancer and a method of diagnosing cancer, which comprise the administration of the antibody of the present invention. Cancers that can be treated by the anti-cancer agent of the present invention include pancreatic cancer, liver cancer, esophageal cancer, melanoma, colorectal cancer, gastric cancer, ovarian cancer, uterine cervical cancer, breast cancer, bladder cancer, brain tumors, and hematological cancers. | 03-11-2010 |
| 20100266502 | Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient - An anti-HB-EGF antibody having an internalizing activity is disclosed. A cytotoxic substance is preferably bound to the anti-HB-EGF antibody of the present invention. Also provided are an anti-cancer agent and a cell proliferation inhibitor, which comprise the antibody of the present invention as an active ingredient, a method of treating cancer and a method of diagnosing cancer, which comprise the administration of the antibody of the present invention. Cancers that can be treated by the anti-cancer agent of the present invention include pancreatic cancer, liver cancer, esophageal cancer, melanoma, colorectal cancer, gastric cancer, ovarian cancer, uterine cervical cancer, breast cancer, bladder cancer, brain tumors, and hematological cancers. | 10-21-2010 |
| 20100273988 | ANTI-CANCER AGENT COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT - A monoclonal antibody having a neutralizing activity on HB-EGF is disclosed. The monoclonal antibody of the present invention is preferably an antibody that does not bind to the HB-EGF protein on the cell surface of HB-EGF-expressing cells. Also provided are an anti-cancer agent and a cell proliferation inhibitor, which comprise the monoclonal antibody of the present invention as an active ingredient, and a method of treating cancer, the method comprising administering the monoclonal antibody of the present invention. Cancers that can be treated by the anti-cancer agent of the present invention include pancreatic cancer, liver cancer, esophageal cancer, melanoma, colorectal cancer, gastric cancer, ovarian cancer, bladder cancer, and brain tumors. | 10-28-2010 |
| 20100298234 | Cancer therapeutic agents comprising a ligand for the neuromedin u receptor 2 (fm4) molecule as an active ingredient - The present inventors discovered that the neuromedin U receptor 2 (FM4) molecule is highly expressed in cancer cells such as pancreatic cancer cells. When the present inventors measured the proliferation-suppressing effect of ligands of this molecule against cancer cells, the ligands were found to have cancer cell proliferation-suppressing effects. The present inventors also discovered that this effect was produced by an FM4 molecule-mediated signal. These findings showed that ligands for the neuromedin U receptor 2 (FM4) molecule are effective for the treatment of cancers with enhanced expression of the neuromedin U receptor 2 (FM4) molecule, including pancreatic cancer, as well as for prevention of metastasis. | 11-25-2010 |
| 20110262929 | ANTI-HS6ST2 ANTIBODIES AND USES THEREOF - The present invention provides antibodies that bind to HS6ST2 proteins, pharmaceutical compositions comprising the antibodies as active ingredients, methods for diagnosing cancer using the antibodies, HS6ST2 proteins conjugated to cytotoxic agents and pharmaceutical compositions comprising the HS6ST2 proteins as active ingredients. | 10-27-2011 |
| 20120282173 | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT - An anti-HB-EGF antibody having an internalizing activity is disclosed. A cytotoxic substance is preferably bound to the anti-HB-EGF antibody of the present invention. Also provided are an anti-cancer agent and a cell proliferation inhibitor, which comprise the antibody of the present invention as an active ingredient, a method of treating cancer and a method of diagnosing cancer, which comprise the administration of the antibody of the present invention. Cancers that can be treated by the anti-cancer agent of the present invention include pancreatic cancer, liver cancer, esophageal cancer, melanoma, colorectal cancer, gastric cancer, ovarian cancer, uterine cervical cancer, breast cancer, bladder cancer, brain tumors, and hematological cancers. | 11-08-2012 |
| Patent application number | Description | Published |
|---|
| 20080274110 | Cell Death-Inducing Agents - To identify antigens of the 2D7 antibody, the present inventors cloned the 2D7 antigen. As a result, the 2D7 antibody was found to recognize HLA class IA. In addition, the present inventors examined whether the 2D7 antibody has cell death-inducing activity. Nuclei fragmentation was observed when the 2D7 antibody was cross-linked with another antibody, indicating that cell-death was induced. Further, diabodies of the 2D7 antibody were found to have very strong cell death-inducing activities, even without the addition of another antibody. These results indicate that minibodies of an HLA-recognizing antibody can be used as cell death-inducing agents. | 11-06-2008 |
| 20100150927 | CELL DEATH INDUCER - An objective of the present invention is to provide an antibody having a high cell death-inducing activity. To solve the above-described problems, the present inventors immunized mice with cells expressing human HLA class IA and human β2 microglobulin (β2M) to obtain monoclonal antibodies. Screening of the obtained antibodies was performed to obtain ten clones of antibodies having a cell death-inducing activity. Analyses of these clones revealed that three of the clones (antibodies C3B3, C11B9, and C17D11), which have the α2 domain of the HLA class I antigen as an epitope, showed a stronger cytotoxic activity when crosslinked with an anti-mouse IgG antibody. Furthermore, when a C3B3 diabody was generated, this diabody was revealed to show a stronger anti-tumor effect compared with conventional diabodies of the 2D7 antibody, which is an HLA class IA antibody. | 06-17-2010 |
| 20120244142 | ANTIBODY CAPABLE OF RECOGNIZING HLA CLASS I - An objective of the present invention is to provide antibodies that recognize HLA class I and have significant cell death-inducing activity. To achieve the above objective, first, the present inventors immunized mice with soluble HLA-A to which a FLAG tag is attached. Four days after the final immunization, spleen cells from the mice were fused with mouse myeloma cells. Then, hybridoma screening was carried out using the cell aggregation-inducing activity and cell death-inducing activity as an index. Thus, the monoclonal antibody F17B1 that has strong cell death-inducing activity was selected. The sequences of the H chain and L chain variable regions of the mouse monoclonal antibody F17B1 were determined to humanize this antibody. Then, the humanized anti-HLA class I antibody H2-G1d_L1-k0 was assessed for cell death induction. The result showed that H2-G1d_L1-k0 suppressed the growth of the IM9 cell line in a concentration dependent manner. | 09-27-2012 |
| Patent application number | Description | Published |
|---|
| 20120182642 | HARD DISK DEVICE, DISK, AND METHOD FOR CALCULATING DISPLACEMENT AMOUNT OR POSITION CORRECTION AMOUNT OF HEAD - A hard disk device includes a disk, a head, and a calculator. The disk includes a plurality of first areas arranged spaced apart in the circumferential direction on a surface of the disk and data-rewritable second areas each located between an adjacent pair of the first areas in the circumferential direction. First servo data is written in the first areas, while second servo data is written in the second areas. The head reads the first servo data and the second servo data written to the surface of the disk. The calculator calculates a displacement amount or a position correction amount of the head based on a result of reading the first servo data and the second servo data by the head. | 07-19-2012 |
| 20120212988 | SEMICONDUCTOR DEVICE - According to an embodiment, a semiconductor device includes a substrate, a connector, a volatile semiconductor memory element, multiple nonvolatile semiconductor memory elements, and a controller. A wiring pattern includes a signal line that is formed between the connector and the controller and that connects the connector to the controller. On the opposite side of the controller to the signal line, the multiple nonvolatile semiconductor memory elements are aligned along the longitudinal direction of the substrate. | 08-23-2012 |
| 20120235141 | SEMICONDUCTOR MEMORY SYSTEM - According to one embodiment, a semiconductor memory system includes a substrate, a plurality of elements and an adhesive portion. The substrate has a multilayer structure in which wiring patterns are formed, and has a substantially rectangle shape in a planar view. The elements are provided and arranged along the long-side direction of a surface layer side of the substrate. The adhesive portion is filled in a gap between the elements and in a gap between the elements and the substrate, where surfaces of the elements are exposed. | 09-20-2012 |
